COMPANY
Location: Minnetonka, MN · source · Oct 12, 2026
Profile checked Oct 10, 2026
Keywords: Non-obstructive Coronary Disease Acute or Chronic Coronary Artery Disease
Timeline
- Trial start —: Simultaneous Measurement of EpicArdial and Microvascular ResisTance Via Angiographic FLOW Study source ↗
- Raise Private equity round — Series A: $25M (total, as published), announced Oct 23, 2025. Source: company's own press page. source ↗
Upcoming milestones
- 2027-12 (ESTIMATED) · · Simultaneous Measurement of EpicArdial and Microvascular ResisTance Via Angiographic FLOW Study · NCT07676097
Estimated primary completion per ClinicalTrials.gov. Dates move.
Funding
Raised: $25.0M. Last 2 years.
- Private equity round — Series A: $25M (total, as published), announced Oct 23, 2025. Source: company's own press page. source ↗
Clinical trials (lead sponsor) 1
| Record | Title | Phase | Status | Start | Primary completion |
|---|
| NCT07676097 | Simultaneous Measurement of EpicArdial and Microvascular ResisTance Via Angiographic FLOW Study | Not listed | Not yet recruiting | 2026-06 | 2027-12 (estimated) |
